Three immunizations with a bivalent human papillomavirus (HPV)-16/18 L1 virus-like particle AS04 vaccine safely induces sustained high levels of antibodies that provide long-term protection against HPV-16 and -18 infection and associated cervical lesions and possibly against HPV 45 and HPV 31-the third and fourth most common HPV types associated with cervical cancer-for up to 4.5 years.
Three immunizations with a bivalent human papillomavirus (HPV)-16/18 L1 virus-like particle AS04 vaccine safely induces sustained high levels of antibodies that provide long-term protection against HPV-16 and -18 infection and associated cervical lesions and possibly against HPV 45 and HPV 31-the third and fourth most common HPV types associated with cervical cancer-for up to 4.5 years.
The information comes from follow-up data from a randomized, multicenter, double-blind, placebo-controlled trial paid for and coordinated by the manufacturer of the vaccine. The findings put the vaccine one step closer to widespread use and prevention of cervical cancer.
The authors of the data found that more than 98% seropositivity was maintained for HPV-16 and -18 during the extended follow-up period. In terms of its efficacy with various HPV-16 and HPV-18 endpoints, the vaccine was 96.9% effective against incident infection, 94.3% effective against the 6-month definition of persistent infection, 100% effective against the 12-month definition of persistent infection, and 100% effective against cervical intraepithelial neoplasia lesions associated with the vaccine types.
Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
Unlocking HPV prevention: Insights from 2022 data on vaccination trends
May 14th 2024Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Understanding pediatric STIs: Trends, management, and more
May 10th 2024Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More